L-dopa and serotonergic neurons: Functional implication and therapeutic perspectives in parkinson's disease

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 4, 2011, Pages 305-320

  Navailles, Sylvia ^a   Carta, Manolo ^b,c   Guthrie, Martin ^a   de Deurwaerdère, Philippe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b LUND UNIVERSITY   (Sweden)

^c Section for Human Physiology and Nutrition ^*  (Italy)

Author keywords

6 hydroxydopamine; Dopamine release; Dyskinesia; L dopa; Non motor complications; Serotonin neurons; Serotonin receptors; Serotonin release

Indexed keywords

DOPAMINE; LEVODOPA;

ARTICLE; BRAIN REGION; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; GOLD STANDARD; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; SEROTONINERGIC NERVE CELL;

EID: 84855758870     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524911106040305     Document Type: Article

References (248)

1. Cotzias, G.C. L-Dopa for Parkinsonism. N. Engl. J. Med., 1968, 278, 630.
2. Hornykiewicz, O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev., 1966, 18, 925-964.
3. Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O.; Jellinger, K.; Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 1973, 20, 415-455.
4. Obeso, J.A., Marin, C.; Rodriguez-Oroz, C.; Blesa, J.; Benitez-Temino, B.; Mena-Segovia, J.; Rodriguez, M.; Olanow, C.W. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann. Neurol., 2008, 64, S30-S46.
5. Hornykiewicz, O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br. Med. Bull., 1973, 29, 172-178.
6. Melamed, E.; Zoldan, J.; Friedberg, G.; Ziv, I.; Weizmann, A. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy. Adv. Neurol., 1996, 69, 545-550.
7. Ungerstedt, U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol., 1968, 5, 107-110.
8. Olsson, M.; Nikkah, G.; Bentlage, C.; Björklund, A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci., 1995, 15, 3863-3875.
9. Burns, R.S.; Chiueh, C.C.; Markey, S.P.; Ebert, M.H.; Jacobowitz, D.M.; Kopin, I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A., 1983, 80, 4546-4550.
10. Jenner, P.; Rupniak, N.M.; Rose, S.; Kelly, E.; Kilpatrick, G.; Lees, A.; Marsden, C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduced parkinsonism in the common marmoset. Neurosci. Lett., 1984, 50, 85-90.
11. Ogawa, N.; Hirose, Y.; Ohara, S.; Ono, T.; Watanabe, Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol., 1985, 50, 435-441.
12. Ungerstedt, U.; Arbuthnott, G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxy-dopamine lesion of the nigrostriatal dopamine system. Brain Res., 1970, 24, 485-493.
13. Henry, B.; Crossman, A.R.; Brotchie, J.M. Characterization of enhanced behavioural responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol., 1998, 151, 334-342.
14. Herrera-Marschitz, M.; Ungerstedt, U. Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur. J. Pharmacol., 1984, 98, 165-176.
15. Hajos, M.; Hjorth, S.; Svensson, K.; Carlsson, A. In vivo dopamine (DA) receptor binding and behavioural effects of the putative DA autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 in rats with a unilateral nigral 6-OH-DA lesion. Exp. Brain Res., 1988, 70, 577-584.
16. Sonsalla, P.K.; Manzino, L.; Heikkila, R.E. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J. Pharmacol. Exp. Ther., 1988, 247, 180-185.
17. Ungerstedt, U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol. Scand. Suppl., 1971, 367, 69-63.
18. Ungerstedt, U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol. Scand. Suppl., 1971, 367, 49-68.
19. Zetterstrom, T.; Herrera-Marschitz, M.; Ungerstedt, U. Simultaneous measurement of dopamine release and rotational behaviour in the 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res., 1986, 376, 1-7.
20. Herrera-Marschitz, M.; Arbuthnott, G.; Ungerstedt, U. The rotational model and microdialysis: significance for dopamine signalling, clinical studies and beyond. Prog. Neurobiol., 2010, 90, 176-189.
21. Pearce, R.K.; Jackson, M.; Smith, L.; Jenner, P.; Marsden, C.D. Chronic L-DOPA administration induces dyskinesias in the 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov. Disord., 1995, 10, 731-740.
22. Cenci, M.A.; Ohlin, K.E. Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15, S13-S17.
23. Olanow, C.W.; Obeso, J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology, 2000, 55, S72-S77.
24. de la Fuente-Fernandez, R.; Sossi, V.; Huang, Z.; Furtado, S.; Lu, J.Q.; Calne, D.B.; Ruth, T.J.; Stoessl, A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain, 2004, 127, 2747-2754.
25. Cenci, M.A.; Lundblad, M. Post-versus presynaptic plasticity in LDOPA- induced dyskinesia. J. Neurochem., 2006, 99, 381-392.
26. Cenci, M.A. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat. Disord., 2007, 13, S263-S267.
27. Abercrombie, E.D.; Bonatz, A.E.; Zigmond, M.J. Effects of L-dopa on extracellular dopamine in striatum of normal and 6- hydroxydopamine-treated rats. Brain Res., 1990, 525, 36-44.
28. Lane, E.L.; Cheetham, S.C.; Jenner, P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp. Neurol., 2006, 197, 284-290.
29. Putterman, D.B.; Munhall, A.C.; Kozell, L.B.; Belknap, J.K.; Johnson, S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factor for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther., 2007, 323, 277-284.
30. Lee, J.; Zhu, W.M.; Stanic, D.; Finkelstein, D.I.; Horne, M.H.; Henderson, J.; Lawrence, A.J.; O'Connor, L.; Tomas, D.; Drago, J.; Horne, M.K. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinesia. Brain, 2008, 131, 1574-1587.
31. Lloyd, K.; Hornykiewicz, O. Parkinson's disease: activity of Ldopa decarboxylase in discrete brain regions. Science, 1970, 170, 1212-1213.
32. Arai, R.; Karazawa, N.; Nagatsu, I. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res., 1996, 706, 177-179.
33. Melamed, E.; Hefti, F.; Liebman, J.; Scholsberg, A.J.; Wurtman, R.J. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease. Nature, 1980, 283, 772-774.
34. Ng, L.K.; Chase, T.N.; Colburn, R.W.; Kopin, I.J. L-Dopa-induced release of cerebral monoamines. Science, 1970, 170, 76-77.
35. Ng, L.K.; Colburn, R.W.; Kopin, I.J. Effects of L-dopa on accumulation and efflux of monoamines in particles of brain homogenates. J. Pharmacol. Exp. Ther., 1972, 183, 316-325.
36. Tison, F.; Mons, N.; Geffard, M.; Henry, P. The metabolism of exogenous L-dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain. J. Neural Transm. Park. Dis. Dement. Sect., 1991, 3, 27-39.
37. Lopez-Real, A.; Rodriguez-Pallares, J.; Guerra, M.J.; Labandeira-Garcia, J.L. Localization and functional significance of striatal neurons immunoreactive to aromatic acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models. Brain Res., 2003, 969, 135-146.
38. Ugrumov, M.V. Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J. Chem. Neuroanat., 2009, 8, 241-256.
39. Kannari, K.; Tanaka, H.; Maeda, T.; Tomiyama, M.; Suda, T.; Matsunaga, M. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J. Neurochem., 2000, 74, 263-269.
40. Lee, W.Y.; Chang, J.W.; Nemeth, N.L.; Kang, U.J. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3,4-dihydroxyphenylalanine administration in Parkinsonian rats. J. Neurosci., 1999, 19, 3266-3274.
41. Bunney, B.S.; Aghajanian, G.K.; Roth, R.H. Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurons. Nat. New Biol., 1973, 245, 123-125.
42. Mercuri, N.B.; Calcbresi, P.; Bernardi, G. Responses of rat substantia nigra compacta neurones to L-DOPA. Br. J. Pharmacol., 1990, 100, 257-260.
43. Harden, D.G.; Grace, A.A. Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment. J. Neurosci., 1995, 15, 6157-6166.
44. Maeda, T.; Kannari, K.; Suda, T.; Matsunaga, M. Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPAderived dopamine release in the dopaminergic denervated stiratum. Brain Res., 1999, 817, 185-191.
45. Miller, D.W.; Abercrombie, E.D. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J. Neurochem., 1999, 72, 1516-1522.
46. Sarre, S.; De Klippel, N.; Herregodts, P.; Ebinger, G.; Michotte, Y. Biotransformation of locally L-dopa in the corpus striatum of the hemi-parkinsonian rats studies with microdialysis. Naunyn Schmiedebergs Arch. Pharmacol., 1994, 350, 15-21.
47. Lindgren, H.S.; Andersson, D.R.; Lagerkvist, S.; Nissbrandt, H.; Cenci, M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem., 2010, 112, 1465-1476.
48. Zigmond, M.J.; Abercrombie, E.D.; Berger, T.W.; Grace, A.A.; Stricker, E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci., 1990, 13, 290-296.
49. Azmitia, E.C.; Segal, M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol., 1978, 179, 641-667.
50. Steinbusch, H.W. Serotonin-immunoreactive neurons and their projections in the CNS. In: Björklund, A.; Hökfelt, T.; Kuhar, M.J. Ed.; Handbook of Chemical Neuroanatomy - Classical transmitters and transmitters receptors in the CNS Part II. Amsterdam, 1984; pp. 68-125.
51. Arai, R.; Karasawa, N.; Nagatsu, I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a doublelabeling immunofluorescence study. Neurosci. Lett., 1995, 195, 195-198.
52. Yamada, H.; Aimi, Y.; Nagatsu, I.; Taki, K.; Kudo, M.; Arai, R. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci. Res., 2007, 59, 1-7.
53. Ng, L.K.; Chase, T.N.; Colburn, R.W.; Kopin, I.J. L-dopa in Parkinsonism. A possible mechanism of action. Neurology, 1972, 22, 688-696.
54. Hollister, A.S.; Breese, G.R.; Mueller, R.A. Role of monoamine neuronal systems in L-dihydroxyphenylalanine-stimulated activity. J. Pharmacol. Exp. Ther., 1979, 208, 37-43.
55. Navailles, S.; Bioulac, B.; Gross, C.; De Deurwaerdère, P. Serotonergic neurons mediate ectopic release of dopamine induced by LDOPA in a rat model of Parkinson's disease. Neurobiol. Dis., 2010, 38, 136-143.
56. Tanaka, H.; Kannari, K.; Maeda, T.; Tomiyama, M.; Suda, T.; Matsunaga, M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport, 1999, 10, 631-634.
57. Kannari, K.; Yamato, H.; Shen, H.; Tomiyama, M.; Suda, T.; Matsunaga, M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J. Neurochem., 2001, 76, 1346-1353.
58. Sprouse, J.S.; Aghajanian, G.K. Electrophysiological responses of serotonergic dorsal raphe enurons to 5-HT1A and 5-HT1B agonists. Synapse, 1987, 1, 3-9.
59. Bosker, F.J.; de Winter, T.Y.; Klompmakers, A.A.; Westenberg, H.G. Flesinoxan dose-dependently reduces extracellular 5- hydroxytryptamine (5-HT) in rat median raphe and dorsal hippocampus through activation of 5-HT1A receptors. J. Neurochem., 1996, 66, 2254-2555.
60. Knobelman, D.A.; Kung, H.F.; Lucki, I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J. Pharmacol. Exp. Ther., 2000, 292, 1111-1117.
61. Riad, M.; Garcia, S.; Watkins, K.C.; Jodoin, N.; Doucet, E.; Langlois, X., el Mestikawy, S.; Hamon, M.; Descarries, L. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol., 2000, 417, 181-194.
62. Sharp, T.; Bramwell, S.R.; Hjorth, S.; Grahame-Smith, D.G. Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br. J. Pharmacol., 1989, 98, 989-997.
63. Adell, A.; Carceller, A.; Artigas, F. In vivo brain dialysis study of the somatodendritic release of serotonin in the Raphe nuclei of the rat: effects of 8-hydroxy-2-(di-n-propylamino)tetralin. J. Neurochem., 1993, 60, 1673-1681.
64. Casanovas, J.M.; Artigas, F. Differential effects of ipsapirone on 5- hydroxytryptamine release in the dorsal and median raphe neuronal pathways. J. Neurochem., 1996, 67, 1945-1952.
65. Yamato, H.; Kannari, K.; Shen, H.; Suda, T.; Matsunaga, M. Fluoxeinte reduces L-DOPA-derived extracellular DA in the 6- OHDA-lesioned rat striatum. Neuroreport, 2001, 12, 1123-1126.
66. Arborelius, L.; Nomikos, G.G.; Grillner, P.; Hertel, P.; Höök, B.B.; Hacksell, U.; Svensson, T.H. 5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 352, 157-165.
67. Sari, Y.; Miquel, M.C.; Brisorgueil, M.J.; Ruiz, G.; Doucet, E.; Hamon, M.; Vergé, D. Cellular and subcellular localization of 5- hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiogramhic and lesion studies. Neuroscience, 1999, 88, 899-915.
68. Adell, A.; Celada, P.; Artigas, F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in tehr at brain. J. Neurochem., 2001, 79, 172-182.
69. Temel, Y.; Boothman, L.J.; Blokland, A.; Magill, P.J.; Steinbusch, H.W. Visser-Vandewalle, V.; Sharp, T. Inhibition of 5-HT neuron activity and induction of depressive-like behaviour by highfrequency stimulation of the subthalamic nucleus. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 17087-17092.
70. Navailles, S.; Benazzouz, A.; Bioulac, B.; Gross, C.; De Deurwaerdère, P. High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J. Neurosci., 2010, 30, 2356-2364.
71. Misoguchi, K.; Yokoo, H.; Yoshida, M.; Tanaka, T.; Tanaka, M. Dopamine formation from L-DOPA administered exogenously is independent of dopaminergic neuronal activity: studies with in vivo microdialysis. Brain Res., 1993, 611, 152-154.
72. Nakamura, K.; Ahmed, M.; Barr, E.; Leiden, J.M.; Kang, U.J. The localization and functional contribution of striatal aromatic Lamino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models. Cell Transplant, 2000, 9, 567-576.
73. Sun, M.; Kong, L.; Wang, X.; Holmes, C.; Gao, Q.; Zhang, G.R.; Pfeilschifter, J.; Goldstein, D.S.; Geller, A.I. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioural correction of a rat model of Parkinson's disease. Hum. Gene Ther., 2004, 15, 1177-1196.
74. Sarre, S.; Herregodts, P.; Deleu, D.; Devrieze, A.; De Klippel, N.; Ebinger, G.; Michotte, Y. Biotransformation of L-dopa in the striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study. Naunyn Schmiedebergs Arch. Pharmacol., 1992, 346, 277-285.
75. Sarre, S.; Smolders, I.; Thorré, K.; Ebinger, G.; Michotte, Y. Biotransformation of locally applied precursors of dopamine, serotonin and noradrenaline in striatum and hippocampus: a microdialysis study. J. Neural Transm., 1997, 104, 1215-1228.
76. Orosz, D.; Bennett, J.P. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat. Exp. Neurol., 1992, 115, 388-393.
77. Molliver, M.E. Serotonergic neuronal systems: what their anatomic organization tells us about function. J. Clin. Psychopharmacol., 1987, 7, 3S-23S.
78. Vertes, R.P. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J. Comp. Neurol., 1991, 313, 643-668.
79. Marti, M.; Trapella, C.; Viaro, R.; Morari, M. The nociceptin/ orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J. Neurosci., 2007, 27, 1297-1307.
80. Seeman, P. Brain dopamine receptors. Pharmacol. Rev., 1980, 32, 229-313.
81. Kostrzewa, R.M. Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev., 1995, 19, 1-17.
82. Tong, J.; Fitzmaurice, P.S.; Ang, L.C.; Furukawa, Y.; Guttman, M.; Kish, S.J. Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol., 2004, 55, 125-129.
83. Przedborski, S.; Jackson-Lewis, V.; Popilskis, S.; Kostic, V.; Levivier, M.; Fahn, S.; Cadet, J.L. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Neurochirurgie, 1991, 37, 377-382.
84. Gnanalingham, K.K.; Smith, L.A.; Hunter, A.J.; Jenner, P.; Marsden, C.D. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse, 1993, 14, 184-194.
85. Svenningsson, P.; Gunne, L.; Andren, P.E. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset. Neuroscience, 2000, 99, 457-468.
86. Nielsen, K.M.; Soghomonian, J.J. Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion. Synapse, 2003, 49, 246-260.
87. Périer, C.; Marin, C.; Jimenez, A.; Bonastre, M.; Tolosa, E.; Hirsch E.C. Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6- hydroxydopamine-lesioned rats. J. Neurochem., 2003, 86, 1328-1337.
88. Konradi, C.; Westin, J.E.; Carta, M.; Eaton, M.E. Kuter, K.; Dekundy, A.; Lundblad, M.; Cenci, M.A. Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis., 2004, 17, 219-236.
89. Shimamura, M.; Shimizu, M.; Yagami, T.; Funabashi, T.; Kimura, F.; Kuroiwa, Y.; Misu, Y.; Goshima, Y. L-3,4- dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase. Neuropharmacology, 2006, 50, 909-916.
90. Soghomonian, J.J. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus. Eur. J. Neurosci., 2006, 23, 2395-2403.
91. Zhang, X.; Andren, P.E.; Svenningsson, P. Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res., 2006, 1095, 207-210.
92. Valastro, B.; Andersson, M.; Lindgren, H.S.; Cenci, M.A. Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB. Neuroscience, 2007, 144, 198-207.
93. Valastro, B.; Dekundy, A.; Krogh, M.; Lundblad, M.; James P.; Danysz, W.; Quack, G.; Cencni, M.A. Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia. J. Neurochem., 2007, 102, 1395-1409.
94. Munoz, A.; Li, Q.; Gardoni, F.; Marcello, E.; Qin, C.; Carlsson, T.; Kirik, D.; Di Luca, M.; Björklund, A.; Bezard, E.; Carta, M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394.
95. Munoz, A.; Carlsson, T.; Tronci, E.; Kirik, D.; Björklund, A.; Carta, M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol., 2009, 219, 298-307.
96. Scholz, B.; Svensson, M.; Alm, H.; Sköld, K.; Fälth, M.; Kultima, K.; Guigoni, C.; Doudnikoff, E.; Li, Q.; Crossman, A.R.; Bezard, E.; Andrén, P.E. Striatal proteomic analysis suggests that first Ldopa dose equates to chronic exposure. PLoS One, 2008, 3, e1589.
97. Lundblad, M.; af Bjerkén, S.; Cenci, M.A.; Pomerleau, F.; Gerhardt, G.A.; Strömberg, I. Chronic intermittent L-DOPA treatment induces changes in dopamine release. J. Neurochem., 2009, 108, 998-1008.
98. McQuade, R.; Sharp, T. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem., 1997, 69, 791-796.
99. Blier, P.; Serrano, A.; Scatton, B. Differential responsiveness of the rat dorsal and median raphe 5-HT systems to 5-HT1 receptor agonists and p-chloroamphetamine. Synapse, 1990, 5, 120-133.
100. Kreiss, D.S.; Lucki, I. Differential regulation of serotonin (5-HT) release in the striatum and hippocampus by 5-HT1A autoreceptors of the dorsal and median raphe nuclei. J. Pharmacol. Exp. Ther., 1994, 269, 1268-1279.
101. Kreiss, D.S.; Lucki, I. Chronic administration of the 5-HT1A receptor agonist 8-OH-DPAT differentially desensitizes 5-HT1A autoreceptors of the dorsal and median raphe nuclei. Synapse, 1997, 25, 107-116.
102. Hervás, I.; Bel, N.; Fernández, A.G.; Palacios, J.M.; Artigas, F. In vivo control of 5- hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei. Naunyn Schmiedebergs Arch. Pharmacol., 1998, 358, 315-322.
103. Van der Kooy, D.; Hattori, T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labelling study in the rat. Brain Res., 1980, 186, 1-7.
104. Invernizzi, R.; Carli, M.; Di Clemente, A.; Samanin, R. Administration of 8-hydroxy-2-(di-n-propylamino)tetralin in raphe nuclei dorsalis and medianus reduces serotonin synthesis in the rat brain: differences in potency and regional sensitivity. J. Neurochem., 1991, 56, 243-247.
105. Casanovas, J.M.; Lésourd, M.; Artigas, F. The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain. Br. J. Pharmacol., 1997, 122, 733-741.
106. Romero, L.; Artigas, F. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J. Neurochem., 1997, 68, 2593-2603.
107. Moore, R.Y.; Halaris, A.E.; Jones, B.E. Serotonin neurons of the midbrain raphe: ascending projections. J. Comp. Neurol., 1978, 180, 417-438.
108. Hopwwod, S.E.; Stamford, J.A. Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphe nuclei. Neuropharmacology, 2001, 40, 508-519.
109. Invernizzi, R.; Velasco, C.; Bramante, M.; Longo, A.; Samanin, R. Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology, 1997, 36, 467-473.
110. Amilhon, B.; Lepicard, E.; Renoir, T.; Mongeau, R.; Popa, D.; Poirel, O.; Miot, S.; Gras, C.; Gardier, A.M.; Gallego, J.; Hamon, M.; Lanfumey, L.; Gasnier, B.; Giros, B.; El Mestikawy S. VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety. J. Neurosci., 2010, 30, 2198-2210.
111. Navailles, S.; Bioulac, B.; Gross, C.; De Deurwaerdère, P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPAinduced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis., 2011, 41, 585-590.
112. Fahn, S.; Libsch, L.R.; Cutler, R.W. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J. Neurol. Sci., 1971, 14, 427-455.
113. Gumpert, J.; Sharpe, D.; Curzon, G. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. J. Neurol. Sci., 1973, 19, 1-12.
114. Korf, J.; van Praag, H.M.; Schut, D.; Nienhuis, R.J.; Lakke, J.P. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy. Eur. Neurol., 1974, 12, 340-350.
115. Lopez, A.; Munoz, A.; Guerra, M.J.; Labandeira-Garcia, J.L. Mechanisms of the effects of exogenous levodopa on the dopamine- denervated striatum. Neuroscience, 2000, 103, 639-651.
116. Misu, Y.; Goshima, Y.; Ueda, H.; Okamura, H. Neurobiology of LDOPAergic systems. Prog. Neurobiol., 1996, 49, 415-454.
117. Schallert, T.; Fleming, S.M.; Leasure, J.L.; Tillerson, J.L.; Bland, S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 2000, 39, 777-787.
118. Carta, M.; Carlsson, T.; Kirik, D.; Björklund, A. Dopamine released from 5-HT terminal sis the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain, 2007, 130, 1819-1833.
119. Chang, J.W.; Watchel, S.R.; Young, D.; Kang, U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience, 1999, 88, 617-628.
120. Winkler, C.; Kirik, D.; Björklund, A.; Cenci, M.A. L-DOPAinduced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis., 2002, 10, 165-186.
121. Spencer, S.E.; Wooten, G.F. Pharmacologic effects of L-dopa are not closely linked temporally to striatal dopamine concentration. Neurology, 1984, 34, 1609-1611.
122. Robertson, G.S.; Robertson, H.A. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci., 1989, 9, 3326-3331.
123. Calabresi, P.; Gubellini, P.; Centonze, D.; Picconi, B.; Bernardi, G.; Chergui, K.; Sveninngsson, P.; Fienberg, A.A.; Greengard, P. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J. Neurosci., 2000, 20, 8443-8451.
124. Picconi, B.; Pisani, A.; Barone, I.; Bonsi, P.; Centonze, D.; Bernardi, G.; Calabresi, P. Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology, 2005, 26, 779-783.
125. Rylander, D.; Parent, M.; O'Sullivan, S.S.; Dovero, S.; Lees, A.J.; Bezard, E.; Descarries, L.; Cenci, M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol., 2010, 68, 619-628.
126. Prescott, I.A.; Dostrovsky, J.O.; Moro E.; Hodaie, M.; Lozano, A.M.; Hutchison, W.D. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Brain, 2009, 132, 309-318.
127. Berthet, A.; Porras, G.; Doudnikoff, E.; Stark, H.; Cador, M.; Bezard, E.; Bloch, B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution of the rat analog of L-DOPA-induced dyskinesia. J. Neurosci., 2009, 29, 4829-4835.
128. Nieoullon, A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol., 2002, 67, 53-83.
129. Carlsson, T.; Carta, M.; Winkler, C.; Björklund, A.; Kirik, D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci., 2007, 27, 8011-8022.
130. Carta, M.; Carlsson, T.; Munoz, A.; Kirik, D.; Björklund, A. Role of serotonin neurons in the induction of levodopa- and graftinduced dyskinesias in Parkinson's disease. Mov. Disord., 2010, 25, S174-S179.
131. Carta, M.; Carlsson, T.; Munoz, A.; Kirik, D.; Bj̈rklund, A. Serotonin- dopamine interaction in the induction and maintenance of LDOPA-induced dyskinesias. Prog. Brain Res., 2008, 172, 465-478.
132. Gomez-Mancilla, B.; Bédard, P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol., 1993, 16, 418-427.
133. Iravani, M.M.; Jackson, M.J.; Kuoppamäki, M.; Smith, L.A.; Jenner, P. 3,4-methylnedioxymethamphetamine (ectasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci., 2003, 23, 9107-9115.
134. Bishop, C.; Taylor, J.L.; Kuhn, D.M.; Eskow, K.L.; Park, J.Y.; Walker, P.D. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci., 2006, 23, 2669-2676.
135. Bonifati, V.; Fabrizio, E.; Cipriani, R.; Vanacore, N.; Meco, G. Buspirone in levopdopa-induced dyskinesias. Clin. Neuropharmacol., 1994, 17, 73-82.
136. Durif, F.; Vidailhet, M.; Bonnet, A.M.; Blin, J.; Agid, Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology, 1995, 45, 1855-1858.
137. Bibbiani, F.; Oh, J.D.; Chase, T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology, 2001, 57, 1829-1834.
138. Kannari, K.; Kurahashi, K.; Tomiyama, M.; Maeda, T.; Arai, A.; Baba, M.; Suda, T.; Matsunaga, M. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei, 2002, 54, 133-137.
139. Goetz, C.G.; Damier, P.; Hicking, C.; Laska, E.; Müller, T.; Olanow, C.W.; Rascol, O.; Russ, H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blinded placebo-controlled trial. Mov. Disord., 2007, 22, 179-186.
140. Eskow, K.L.; Gupta, V.; Alam, S.; Park, J.Y.; Bishop, C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l- DOPA efficacy. Pharmacol. Biochem. Behav., 2007, 87, 306-314.
141. Iravani, M.M.; Tayarani-Binazir, K.; Chu, W.B.; Jackson, M.J.; Jenner, P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8- OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J. Pharmacol. Exp. Ther., 2006, 319, 1225-1234.
142. Dupre, K.B.; Eskow, K.L.; Negron, G.; Bishop, C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptormediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res., 2007, 1158, 135-143.
143. Dupre, K.B.; Eskow, K.L.; Steiniger, A.; Klioueva, A.; Negron, G.E.; Lormand, L.; Park, J.Y.; Bishop, C. Effects of coincident 5- HT1A receptor situation and NMDA receptor antagonism on LDOPA- induced dyskinesia and rotational behaviors in the hemiparkinsonian rat. Psychopharmacology (Berl.), 2008, 199, 99-108.
144. Olanow, C.W.; Damier, P.; Goetz, C.G.; Mueller, T.; Nutt, J.; Rascol, O.; Serbanescu, A.; Deckers, F.; Russ, H. Multicenter, openlabel, trial of sarizotan in Parkinson disease patients with levodopainduced dyskinesias (the SPLENDID study). Clin. Neuropharmacol., 2004, 27, 58-62.
145. Bara-Jimenez, W.; Bibbiani, F.; Morris, M.J.; Dimitrova, T.; Sherzai, A.; Mouradian, M.M.; Chase, T.N. Effects of serotonin 5- HT1A agonist in advanced Parkinson's disease. Mov. Disord., 2005, 20, 932-936.
146. Jackson, M.J.; Al-Barghouthy, G.; Pearce, R.K.; Smith, L.; Hagan, J.J.; Jenner, P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol. Biochem. Behav., 2004, 79, 391-400.
147. Mignon, L.; Wolf, W.A. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology (Berl.), 2007, 192, 49-59.
148. Eskow, K.L.; Dupre, K.B.; Barnum, C.J.; Dickinson, S.O.; Park, J.Y.; Bishop, C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse, 2009, 63, 610-620.
149. Jaunarajs, K.L.; Dupre, K.B.; Steiniger, A.; Klioueva, A.; Moore, A.; Kelly, C.; Bishop, C. Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. Neuroreport, 2009, 20, 1265-1269.
150. Ulusoy, A.; Sahin, G.; Kirik, D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 13159-13164.
151. Goodwin, G.M.; De Souza, R.J.; Wood, A.J.; Green, A.R. The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a postsynaptic mechanism. Psychopharmacology (Berl.), 1986, 90, 488-493.
152. Yamada, J.; Sugimoto, Y.; Horisaka, K. The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur. J. Pharmacol., 1988, 154, 299-304.
153. Meissner, W.; Ravenscroft, P.; Reese, R.; Harnack, D.; Morgenstern, R.; Kupsch, A.; Klitgaard, H.; Bioulac, B.; Gross, C.; Bezard, E.; Boraud, T. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis., 2006, 22, 586-598.
154. Berthet, A.; Bézard, E. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat. Disord., 2009, 15, S8-S12.
155. Ahmed, M.R.; Berthet, A.; Bychkov, E.; Porras, G.; Li, Q.; Bioulac, B.H.; Carl Y.T.; Bloch, B.; Kook, S.; Aubert, I.; Devoro, S.; Doudnikoff, E.; Gurevich, V.V.; Gurevich, E.V.; Bezard, E. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci. Transl. Med., 2010, 21, 28ra28.
156. Belujon, P.; Lodge, D.J.; Grace, A.A. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Mov. Disord., 2010, 25, 1568-1576.
157. Lane, E.L.; Cheetham, S.C.; Jenner, P. Dopamine uptake inhibitorinduced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5- hydroxytryptamine and noradrenaline receptors. J. Pharmacol. Exp. Ther., 2005, 312, 1124-1131.
158. Mignon, L.; Wolf, W.A. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl.), 2002, 163, 85-94.
159. Di Matteo, V.; Pierucci, M.; Esposito, E.; Cresimanno, G.; Benigno, A.; Di Giovanni, G. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog. Brain Res., 2008, 172, 423-463.
160. Kuan, W.L.; Zhao, J.W.; Barker, R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl.), 2008, 197, 279-293.
161. Pazos, A.; Palacios, J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res., 1985, 346, 205-230.
162. Chalmers, D.T.; Watson, S.J. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain-a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res., 1991, 561, 51-60.
163. Pompeiano, M.; Palacios, J.M.; Mengod, G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 1992, 12, 440-453.
164. Bruinvels, A.T.; Landwehrmeyer, B.; Gustafson, E.L.; Durkin, M.M.; Mengod, G.; Branchek, T.A.; Hoyer, D.; Palacios, J.M. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology, 1994, 33, 367-386.
165. Hamon, M.; Gozlan, H.; el Mestikawy, S.; Emerit, M.B.; Bolanos, F.; Schechter, L. The central 5-HT1A receptors: pharmacological, biochemical, functional and regulatory properties. Ann. N. Y. Acad. Sci., 1990, 600, 114-129.
166. Navailles, S.; De Deurwaerdère, P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl.), 2011, 213, 213-242. Review
167. Frechilla, D.; Cobreros, A.; Salside, L.; Moratalla, R.; Insausti, R.; Luquin, M.; Del Rio, J. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse, 2001, 39, 288-296.
168. Antonelli, T.; Fuxe, K.; Tomasini, M.C.; Bartoszyk, G.D.; Seyfried, C.A.; Tanganelli, S.; Ferraro, L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse, 2005, 58, 193-199.
169. Chen, CP.; Alder, J.T.; Bray, L.; Kingsbury, A.E.; Francis, P.T.; Foster, O.J. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann. N. Y. Acad. Sci., 1998, 15, 288-289.
170. Bonaventure, P.; Voorn, P.; Luyten, W.H.; Jurzak, M.; Schotte, A.; Leysen, J.E. Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function. Neuroscience, 1998, 82, 469-484.
171. Zhang, X.; Andren, P.E.; Greengard, P.; Svenningsson, P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in LDOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 2163-2168.
172. Dijk, S.N.; Francis, P.T.; Stratmann, G.C.; Bowen, D.M. NMDAinduced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br. J. Pharmacol., 1995, 115, 1169-1174.
173. Mignon, L.; Wolf, W.A. 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport, 2005, 16, 699-703.
174. Bishop, C.; Krolewski, D.M.; Eskow, K.L.; Barnum, C.J.; Dupre, K.B.; Deak, T.; Walker, P.D. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res., 2009, 87, 1645-1658.
175. Marin, C.; Aguilar, E.; Rodriguez-Oroz, M.C.; Bartoszyk, G.D.; Obeso, J.A. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDAlesioned rats. Psychopharmacology (Berl.), 2009, 204, 241-250.
176. Ikeguchi, K.; Kuroda, A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur. Arch. Psychiatry Clin. Neurosci., 1995, 244, 320-324.
177. Zoldan, J.; Friedberg, G.; Livneh, M.; Melamed, E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology, 1995, 45, 1305-1308.
178. Durif, F.; Vidailhet, M.; Assal, F.; Roche, C.; Bonnet, A.M.; Agid, Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology, 1997, 48, 658-662.
179. Nicholson, S.L.; Brotchie, J.M. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol., 2002, S3, 1-6.
180. Di Giovanni, G.; Di Matteo, V.; Pierucci, M.; Benigno, A.; Esposito, E. Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies? Curr. Med. Chem., 2006, 13, 3069-3081.
181. De Deurwaerdère, P.; Mignon, L.; Chesselet, M.F. Physiological and pathophysiological aspects of 5-HT2C receptors in basal ganglia. In: The Pathophysiology of Central 5-HT2C Receptors; Di Giovanni, G. Ed.; In: The receptors series; Neve, K. Ed.; Humana Press, Springer, 2010.
182. Kienzl, E.; Riederer, P.; Jellinger, K.; Wesemann, W. Transitional states of central serotonin receptors in Parkinson's disease. J. Neural Transm., 1981, 51, 113-122.
183. Weiner, D.M.; Vanover, K.E.; Brann, M.R.; Meltzer, H.Y.; Davis, R.E. Psychosis of Parkinson's disease: serotonin 2A inverse agonists as potential therapeutics. Curr. Opin. Investig. Drugs, 2003, 4, 815-819.
184. Rabey, J.M. Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat. Disord., 2009, 15, S105-S110.
185. Meltzer, H.Y.; Mills, R.; Revell, S.; Williams, H.; Johnson, A.; Bahr, D.; Friedman, J.H. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology, 2010, 35, 881-892.
186. Ballanger, B.; Strafella, A.P.; van Eimeren, T.; Zurowski, M.; Rusjan, P.M.; Houle, S.; Fox, S.H. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol., 2010, 67, 416-421.
187. Meco, G.; Stirpe, P.; Edito, F.; Purcaro, C.; Valente, M.; Bernardi, S.; Vanacore, N. Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. J. Neural Transm., 2009, 116, 881-884.
188. Vanover, K.E.; Betz, A.J.; Weber, S.M.; Bibbiani, F.; Kielaite, A.; Weiner, D.M.; Davis, R.E.; Chase, T.N.; Salamone, J.D. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav., 2008, 90, 540-544.
189. Ferguson, M.C.; Nayyar, T.; Deutch, A.Y.; Ansah, T.A. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology, 2010, 59, 31-36.
190. Fox, S.H.; Brotchie, J.M. Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. Eur. J. Pharmacol., 1996, 301, 27-30.
191. Fox, S.H.; Moser, B.; Brotchie, J.M. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol., 1998, 151, 35-49.
192. Fox, S.H.; Brotchie, J.M. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol., 2000, 398, 59-64.
193. Fox, S.H.; Brotchie, J.M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord., 2000, 15, 1046-1049.
194. Werneck, A.L.; Rosso, A.L.; Vincent, M.B. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson's disease. Arq. Neuropsiquiatr., 2009, 67, 407-412.
195. De Deurwaerdère, P.; Chesselet, M.F. Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats. J. Neurosci., 2000, 20, 5170-5178.
196. Kostrzewa, R.M.; Huang, N.Y.; Kostrzewa, J.P.; Nowak, P.; Brus, R. Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox. Res., 2007, 11, 41-50.
197. Di Monte, D.A.; DeLanney, L.E.; Irwin, I.; Royland, J.E.; Chan, P.; Jakowec, M.W.; Langston, J.W. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of LDOPA-treated monkeys. Brain Res., 1996, 738, 53-59.
198. Finberg, J.P.; Lamensdorf, I.; Commissiong, J.W.; Youdim, M.B. Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. Suppl., 1996, 48, 95-101.
199. Bartholini, G.; Da Prada, M.; Pletscher, A. Decrease of cerebral 5- hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J. Pharm. Pharmacol., 1968, 20, 228-229.
200. Biggs, C.S.; Starr, M.S. Dopamine and glutamate control each other's release in the basal ganglia: a microdialysis study of the entopeduncular nucleus and substantia nigra. Neurosci. Biobehav., 1997, 21, 497-504.
201. Thorré, K.; Sarre, S.; Smolders, I.; Ebinger, G.; Michotte, Y. Dopaminergic regulation of serotonin release in the subtantia nigra of the freely moving rat using microdialysis. Brain Res., 1998, 796, 107-116.
202. Héry, F.; Simonnet, G.; Bourgoin, S.; Soubrié, P.; Artaud, F.; Hamon, M.; Glowinski, J. Effect of nerve activity on the in vivo release of [3H]serotonin continuously formed from L-[3H]tryptophan in the caudate nucleus of the cat. Brain Res., 1979, 169, 317-334.
203. Everett, G.M.; Borcherding, J.W. L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science, 1970, 168, 849-850.
204. Zhou, F.M.; Liang, Y.; Salas, R.; Zhang, L.; De Biasi, M.; Dani, J.A. Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron, 2005, 46, 65-74.
205. Gil, S.; Park, C.; Lee, J.; Koh, H. The roles of striatal serotonin and L: -amino-acid decarboxylase on L: -DOPA-induced Dyskinesia in a Hemiparkinsonian rat model. Cell Mol. Neurobiol., 2010, 30, 817-825.
206. Kish, S.J. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv. Neurol., 2003, 91, 39-49.
207. Scholtissen, B.; Verhey, F.R.; Steinbusch, H.W.; Leentjens, A.F. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J. Neural Transm., 2006, 113, 59-73.
208. Scatton, B.; Javoy-Agid, F.; Rouquier, L.; Dubois, B.; Agid, Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res., 1983, 275, 321-328.
209. Birkmayer, W.; Birkmayer, J.D. Dopamine action and disorders of neurotransmitter balance. Gerontology, 1987, 33, 168-171.
210. Kish, S.J.; Tong, J.; Hornykiewicz, O.; Rajput, A.; Chang, L.J.; Guttman, M.; Furukawa, Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain, 2008, 131, 120-131.
211. Kerenyi, L.; Ricaurte, G.A.; Schretlen, D.J.; McCann, U.; Varga, J.; Mathews, W.B.; Ravert, H.T.; Dannals, R.F.; Hilton, J.; Wong, D.F.; Szabo, Z. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch. Neurol., 2003, 60, 1123-1129.
212. Politis, M.; Wu, K.; Loane, C.; Kiferle, L.; Molloy, S.; Brooks, D.J.; Piccini, P. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis., 2010, 40, 216-221.
213. Doder, M.; Rabiner, E.A.; Turjanski, N.; Lees, A.J.; Brooks, D.J.; 11C-WAY 100635 PET study. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology, 2003, 60, 601-605.
214. Jellinger, K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol., 1991, 14, 153-197.
215. Halliday, G.M.; Blumbergs, P.C.; Cotton, R.G.; Blessing, W.W.; Geffen, L.B. Loss of brainstem serotonin - and substance Pcontaining neurons in Parkinson's disease. Brain Res., 1990, 510, 104-107.
216. Kovacs, G.G.; Klöppel, S.; Fischer, I.; Dorner, S.; Lindeck-Pozza, E.; Birner, P.; Bötefür, I.C.; Pilz, P.; Volk, B.; Budka, H. Nucleusspecific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport, 2003, 14, 73-76.
217. Tohgi, H.; Abe, T.; Takahashi, S.; Takahashi, J.; Hamato, H. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neurosci. Lett., 1993, 159, 135-138.
218. Reader, T.A.; Dewar, K.M. Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson's disease. Neurochem. Int., 1999, 34, 1-21.
219. Kääriäinen, T.M.; Garcia-Horsman, J.A.; Piltonen, M.; Huotari, M.; Männistö, P.T. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions. Basic Clin. Pharmacol. Toxicol., 2008, 102, 300-307.
220. Kääriäinen, T.M.; Garcia-Horsman, J.A.; Piltonen, M.; Männistö, P.T. L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats. Neuroreport, 2009, 20, 313-318.
221. Carta, M.; Lindgren, H.S.; Lundblad, M.; Stancampiano, R.; Fadda, F.; Cenci, M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem., 2006, 96, 1718-1727.
222. Zeng, B.Y.; Iravani, M.M.; Jackson, M.J.; Rose, S.; Parent, A.; Jenner, P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol. Dis., 2010, 40, 599-607.
223. Fox, S.H.; Chuang, R.; Brotchie, J.M. Serotonin and Parkinson's disease: on movement, mood and madness. Mov. Disord., 2009, 24, 1255-1266.
224. Chase, T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology, 1998, 50, S17-S25.
225. Lee, W.Y.; Lee, E.A.; Jeon, M.Y.; Kang, H.Y.; Park, Y.G. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydrophenylalanine administration. Exp. Neurol., 2006, 197, 215-224.
226. Lacombe, E.; Carcenac, C.; Boulet, S.; Feurstein, C.; Bertrand, A.; Poupard, A.; Savasta, M. High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute L-3,4-dihydroxyphenylalanine in dopaminergic denervated rats. Eur. J. Neurosci., 2007, 26, 1670-1680.
227. Nimura, T.; Yamaguchi, K.; Ando, T.; Shibuya, S.; Oikawa, T.; Nakagawa, A.; Shirane, R.; Itoh, M.; Tominaga, T. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. J. Neurosurg., 2005, 103, 968-973.
228. Voon, V.; Fernagut, P.O.; Wickens, J.; Baunez, C.; Rodriguez, M.; Pavon, N.; Juncos, J.L.; Obeso, J.A.; Bezard, E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse disorders. Lancet Neurol., 2009, 8, 1140-1149.
229. Siri, C.; Cilia, R.; De Gaspari, D.; Canesi, M.; Meucci, N.; Zecchinelli, A.L.; Pezzoli, G.; Antonini, A. Cognitive status of patients with Parkinson's disease and pathological gambling. J. Neurol., 2010, 257, 247-252.
230. Zhang, X.; Andren, P.E.; Svenningsson, P. Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson's disease model. Physiol. Behav., 2007, 92, 29-33.
231. Scholtissen, B.; Verhey, F.R.; Adam, J.J.; Weber, W.; Leentjens, A.F. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance. Clin. Neuropharmacol., 2006, 29, 276-285.
232. Chen, C.P.; Alder, J.T.; Bray, L.; Kingsbury, A.E.; Francis, P.T.; Foster, O.J. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann. N. Y. Acad. Sci., 1998, 861, 288-289.
233. Mayeux, R. The "serotonin hypothesis" for depression in Parkinson's disease. Adv. Neurol., 1990, 53, 163-166.
234. Smith, K.A.; Fairburn, C.G.; Cowen, P.J. Relapse of depression after rapid depletion of tryptophan. Lancet, 1997, 349, 915-919.
235. Bhagwagar, Z.; Whale, R.; Cowen, P.J. State and trait abnormalities in serotonin function in major depression. Br. J. Psychiatry, 2002, 180, 24-28.
236. Burnet, P.W.; Chen, C.P.; McGowan, S.; Franklin, M.; Harrison, P.J. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience, 1996, 73, 531-540.
237. Meltzer, H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology, 1999, 21, 106S-115S.
238. Celada, P.; Puig, M.; Amargos-Bosch, M.; Adell, A.; Artigas, F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci., 2004, 29, 252-265.
239. Cools, R.; Barker, R.A.; Sahakian, B.J.; Robbins, T.W. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb. Cortex, 2001, 11, 1136-1143.
240. Frank, M.; Seeberger, L.; O'Reilly, R. By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism. Science, 2004, 306, 1940-1943.
241. Pavese, N.; Metta, V.; Bose, S.K.; Chaudhuri, K.R.; Brooks, D.J. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain, 2010, 133, 3434-3443.
242. Fernandez, H.H.; Friedman, J.H.; Jacques, C.; Rosenfeld, M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord., 1999, 14, 484-487.
243. Weintraub, D.; Morales, K.H.; Moberg, P.J.; Bilker, W.B.; Balderston, C.; Duda, J.E.; Katz, I.R. Stern, M.B. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov. Disord., 2005, 20, 1161-1169.
244. Ehrt, U.; Bronnick, K.; Leentkens, A.F.; Larsen, J.P.; Aarsland, D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int. J. Geriatr. Psychiatry, 2006, 21, 252-258.
245. Leentjens, A.F.; Scholtissen, B.; Vreeling, F.W.; Verhey, F.R. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neurospychopharmacology, 2006, 31, 1009-1015.
246. Lemke, M.R. Depressive symptoms in Parkinson's disease. Eur. J. Neurol., 2008, 15, 21-25.
247. Zahodne, L.B.; Fernandez, H.H. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging, 2008, 25, 665-682.
248. Eskow Jaunarajs, K.L.; Dupre, K.B.; Ostock, C.Y.; Button, T.; Deak, T.; Bishop, C. Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav. Pharmacol., 2010, 21, 627-637.